Sublingual MPL allergy vaccines - Allergy Therapeutics
Alternative Names: Sublingual MPLLatest Information Update: 02 Oct 2021
At a glance
- Originator Allergy Therapeutics
- Class Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-rhinitis(Prevention) in Germany (Sublingual, Drops)
- 20 Sep 2013 Phase I development is ongoing